Open AccessUSING QCT TO DETECT DRUG-INDUCED OSTEOPOROSIS IN PATIENTS WITH MENTAL DISORDERS
Author(s) -
N. I. Ananyeva,
S. E. Likhonosova,
Н. Г. Незнанов,
Г. Н. Мазо,
Р. Ф. Насырова,
Nataliya Shnayder,
Л. В. Липатова,
К. Рыбакова,
L V Malyshko,
F. Sh. Gadgieva,
Yu. V. Kocyubinskaya,
Е. В. Андреев
Publication year - 2019
Publication title -
lučevaâ diagnostika i terapiâ
Language(s) - English
Resource type - Journals
eISSN - 2079-5351
pISSN - 2079-5343
DOI - 10.22328/2079-5343-2019-10-3-77-85
Subject(s) - osteoporosis , medicine , antipsychotic , antipsychotic drug , schizophrenia (object oriented programming) , drug , pharmacotherapy , psychiatry , physical therapy
In clinical practice, the assessment of the cumulative risk of drug-induced osteoporosis in patients with mental disorders is difficult because there are no algorithms to reveal patients with a high risk of antipsychotic-induced osteoporosis and BMD is not evaluated in patients with mental disorders. 95 patients aged from 21 to 60 years with a mental illness duration of at least 12 months on antipsychotics and anticonvulsants therapy were examined. 23 patients (24%) had shown a violation of BMD. There is a significant correlation between the number of risk factors and a decrease in BMD. However, additional study of pharmacogenetic and laboratory data on the risk of osteoporosis is required, which will make it possible to plan therapy more precisely, additionally prescribe drugs that regulate BMD in these categories of patients.